Biomarkers for assessing occupational exposures to 1,3-butadiene.
The overall objective of this study was to evaluate a continuum of biomarkers in blood and urine for their sensitivities as indicators of low level occupational exposures to 1,3 butadiene (BD). The study design was largely cross-sectional, with biological samples collected within a short timeframe. Personal 8-h BD exposure measures were made on several occasions over a 60-day period for each potentially exposed worker in order provide maximum accuracy for this independent variable and to accommodate the different expression intervals of the several biomarkers. Co-exposures to styrene, toluene and benzene were also measured. The study included 24 BD monomer production workers (mean BD exposure=0.642 mg/m(3)), 34 polymerization workers (mean BD exposure=1.794 mg/m(3)) and 25 controls (mean BD exposure=0.023 mg/m(3)). The several biomarkers were measured by a consortium of investigators at different locations in the US and Europe. These biomarkers included: (1) metabolic genotypes (CYP2E1, EH, GST M1, GST T1, ADH2, ADH3), determined in Prague and Burlington, VT; (2) urinary M1 and M2 metabolites (1,2-dihydroxy-4-[N-acetylcysteinyl]-butane and 1-hydroxy-2-[N-acetylcysteinyl]-3-butene, respectively), determined in Albuquerque, NM and Leiden; (3) hemoglobin adducts (N-[2-dihydroxy-3-butenyl]valine=HBVal and N-[2,3,4-trihydroxybutyl]valine=THBVal), determined in Amsterdam and Chapel Hill, NC, respectively; (4) HPRT mutations determined by autoradiographic assay in Galveston, TX, with slides re-read in Burlington, VT; (6) hypoxanthine-guanine phosphoribosyltransferase (HPRT) mutations determined by cloning assay in Leiden with mutational spectra characterized in Burlington, VT; (7) sister chromatid exchanges and chromosome aberrations determined by standard methods and FISH analysis in Prague. Urinary M1 and M2 metabolites and HBVal and THBVal hemoglobin adducts were all significantly correlated with BD exposure levels, with adducts being the most highly associated. No significant relationships were observed between BD exposures and HPRT mutations or any of the cytogenetic endpoints, regardless of method of assay.
Albertini
R J
RJ
Genetic Toxicology Laboratory, University of Vermont, 32 N. Prospect Street, Burlington, VT 05401, USA. ralbertini@mose.uvm.edu
Sram
R J
RJ
Vacek
P M
PM
Lynch
J
J
Wright
M
M
Nicklas
J A
JA
Boogaard
P J
PJ
Henderson
R F
RF
Swenberg
J A
JA
Tates
A D
AD
Ward
J B
JB
D000328:Adult; D001554:Benzene / Q000633:toxicity; D015415:Biomarkers / Q000097:blood / Q000652:urine; D002070:Butadienes / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000633:toxicity*; D003430:Cross-Sectional Studies; D003582:Cytogenetics; D006454:Hemoglobins / Q000187:drug effects; D006801:Humans; D007041:Hypoxanthine Phosphoribosyltransferase / Q000235:genetics; D008297:Male; D009154:Mutation; D016273:Occupational Exposure; D018570:Risk Assessment; D020058:Styrene / Q000633:toxicity; D014050:Toluene / Q000633:toxicity
D015415:Biomarkers; D002070:Butadienes; D006454:Hemoglobins; D014050:Toluene; D020058:Styrene; D007041:Hypoxanthine Phosphoribosyltransferase; D001554:Benzene; C031763:1,3-butadiene